A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

March 15, 2016

Study Completion Date

June 10, 2016

Conditions

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

DRUG

CCX168

Administered orally.

DRUG

Midazolam

Administered orally.

DRUG

Celecoxib

Administered orally.

DRUG

Itraconazole

Administered orally.

DRUG

Rifampicin

Administered orally.

Trial Locations (1)

Celerion, Tempe